General descriptionThis product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the
issuing Pharmacopoeia.
ApplicationRabeprazole for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol ActionsRabeprazole sodium is gastric proton pump inhibitor. It suppresses the production of acid in the stomach by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Rabeprazole sodium has been used clinically to treat acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevent gastroinetestinal bleeds associated with NSAID use.
Rabeprazole sodium is gastric proton pump inhibitor; antiulcerative.
PackagingThe product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the
EDQM reference substance catalogue.
Other NotesSales restrictions may apply.